medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (2)

Pain in sickle cell disease

Concepción FY, Agramonte LOM, Quintero SY

Language: Spanish
References: 20
Page: 1-10
PDF size: 295.23 Kb.


ABSTRACT

Introduction: Sickle cell disease includes a group of genetically inherited disorders in which, at low oxygen saturation, aggregation of rigid polymers of deoxygenated hemoglobin S occurs. Pain is the main clinical characteristic of sickle cell disease. It is the first cause of hospitalization. It is basically of nociceptive type. Patients with sickle cell disease can present various types of pain depending on the injured structures; the musculoskeletal type is the most frequent.
Objective: To analyze the main therapeutic modalities for pain management in sickle cell disease.
Methods: A literature review was carried out, in English and in Spanish, through the PubMed website and the Google Scholar search engine, of articles published in the last five years. Analysis and summary of the revised bibliography was made.
Information analysis and synthesis: Currently, there are several treatment options. The basis for pain management is the recognition and evaluation of severity, since analgesic treatment will depend on this. Once pain is established, initial management should focus on providing rapid control, guaranteeing therapeutic doses of drugs, and avoiding the onset of complications.
Conclusion: Adequate treatment and follow-up of patients with pain in sickle cell disease should be maintained, as this will reduce, as much as possible, the complications that the disease can cause in patients from an organic and psychological point of view.


REFERENCES

  1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organization. 2008;86:480-7.

  2. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, et al. Global distribution of the sickle cell gene and geographical confrmation of the malaria hypothesis. Nat Commun 2010;1:104.

  3. Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol 2011;154:736-44.

  4. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: Frequency, etiology, and prognostic signifcance. Am J Hematol. 2005;79:17-25.

  5. Ballas K. Current Issues in Sickle Cell Pain and Its Management. Hematology. 2007;97-105.

  6. Nagalapuram V, Kulkarni V, Leach J, Aban I, Sirigaddi K, Lebensburger JD, et al. Effect of Sickle Cell Anemia Therapies on the Natural History of Growth and Puberty Patterns. J Pediatric Hematol Oncol. 2019 Apr 3. doi: 10.1097/MPH.0000000000001477.

  7. Niscola P, Sorrentino F, Scaramucci L, Cianciulli P. Pain Syndromes in sickle cell disease: An update. Pain Med 2009; 10(3):470-80.

  8. Lebensburger JD, Patel RJ, Palabindela P, Bemrich-Stolz CJ, Howard TH, Hilliard LM. Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia. J Blood Med. 2015 Dec 15;6:285-90. doi: 10.2147/JBM.S97405.

  9. Bemrich-Stolz CJ, Halanych JH, Howard TH, Hilliard LM, Lebensburger JD. Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease. Int J HematolTher. 2015;1(1). doi: 10.15436/2381-1404.15.003.

  10. Payne J, Aban I, Hilliard LM, Madison J, Bemrich-Stolz C, Howard TH, et al. Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis. Pediatr Blood Cancer. 2018 Dec;65(12) e27420. doi: 10.1002/pbc.27420.

  11. Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88(11):932-8.

  12. Cronin RM, Dorner TL, Utrankar A, Allen W, Rodeghier M, Kassim AA et al. El aumento de la activación del paciente se asocia con menos visitas a la sala de emergencias y hospitalizaciones por dolor en adultos en adultos con enfermedad de células falciformes. Pain Med. 2018. Doi: 10 1093/pm/pny194.

  13. LeBlanc Z, Vance C, Payne J, Zhang J, Hilliard L, Lebensburger JD, et al. Management of severe chronic pain with methadone in pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2018 Aug;65(8):e27084. doi: 10.1002/pbc.27084.

  14. Eccleston C, Palermo T, Williams A, Lewandowski A, Morley S. Psychological therapies for the management of chronic and recurrent pain in children and adolescent. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003968. doi: 10.1002/14651858.CD003968.pub2.

  15. Baddam S, Cutter GR, Wolfson JA, Friedman GK, Lebensburger JD. Publication outcomes of abstracts from the American Society of Hematology Annual Meeting. Am J Hematol. 2017 May;92(5): E81-E83. doi: 10.1002/ajh.24695.

  16. Hilliard LM, Kulkarni V, Sen B, Caldwell C, Bemrich-Stolz C, Howard TH, et al. Red blood cell transfusion therapy for sickle cell patients with frequent painful events. Pediatr Blood Cancer. 2018;65(12): e27423.

  17. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699-710.

  18. Martínez Triana R, García Hernández A, Guerra González EM, Machado Almeida T, Reytor Alfonso K. Efecto de la drepanocitosis sobre la calidad de vida. Rev Cub Hematol Inmunol Hemoter. 2015 [acceso 30/04/2019];31(3):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/261

  19. Jonassaint CR, Jones VL, Leong S, Frierson GM. A systematic review of the association between depression and health care utilization in children and adults with sickle cell disease. Br J Haematol.2016;174(1):136-47.

  20. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Systematic Reviews. 2015;5:CD001916. DOI: 10.1002/14651858.CD001916.pub3.




2020     |     www.medigraphic.com